- Home
- SLNO
as 01-21-2025 4:00pm EST
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 1.9B | IPO Year: | 2014 |
| Target Price: | $74.83 | AVG Volume (30 days): | 567.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $36.61 - $60.92 | Next Earning Date: | 03-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Soleno Therapeutics Inc. (SLNO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mackaness James H | SLNO | CHIEF FINANCIAL OFFICER | Jan 2 '25 | Sell | $45.82 | 7,874 | $360,460.44 | 115,410 | |
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Jan 2 '25 | Sell | $45.82 | 21,091 | $965,515.52 | 709,476 | |
| Yen Kristen | SLNO | SEE REMARKS | Jan 2 '25 | Sell | $45.82 | 4,860 | $222,483.86 | 78,945 | |
| Hirano Patricia C | SLNO | SEE REMARKS | Jan 2 '25 | Sell | $45.82 | 3,030 | $138,709.47 | 107,485 |
Latest Soleno Therapeutics Inc. News
SLNO Breaking Stock News: Dive into SLNO Ticker-Specific Updates for Smart Investing
Insider Monkey
9 days ago
Is Soleno Therapeutics (SLNO) the Top Small Cap Stock to Buy with the Highest Upside Potential?
Simply Wall St.
15 days ago
Soleno Therapeutics, Inc. (NASDAQ:SLNO): When Will It Breakeven?
MT Newswires
a month ago
Soleno Therapeutics Gets $200 Million Debt Financing From Oxford Finance
GlobeNewswire
a month ago
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
Simply Wall St.
2 months ago
High Growth Tech Stocks to Watch in November 2024
GlobeNewswire
2 months ago
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Pharmaceutical Technology
2 months ago
FDA delays decision of Soleno’s Prader-Willi syndrome drug
BioPharma Dive
2 months ago
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
Compare SLNO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLNO Soleno Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.